{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:33:14Z","timestamp":1790983994352,"version":"4.1.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"6-7","license":[{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2004,7,1]],"date-time":"2004-07-01T00:00:00Z","timestamp":1088640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2004,7]]},"DOI":"10.1016\/j.biopha.2004.02.006","type":"journal-article","created":{"date-parts":[[2004,6,9]],"date-time":"2004-06-09T16:23:03Z","timestamp":1086798183000},"page":"372-380","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route"],"prefix":"10.1016","volume":"58","author":[{"given":"Linda M","family":"Hiebert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M","family":"Wice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilly","family":"Ping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2004.02.006_BIB1","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/infdis\/158.5.1084","article-title":"Activity of dextran sulfate and other polyanionic polysaccharides against human immunodeficiency virus","volume":"158","author":"Bagasra","year":"1988","journal-title":"J Infect Dis"},{"key":"10.1016\/j.biopha.2004.02.006_BIB2","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1001\/archinte.1997.00440420107010","article-title":"Inability of the activated thromboplastin time to predict heparin levels","volume":"157","author":"Baker","year":"2002","journal-title":"Arch Int Med"},{"key":"10.1016\/j.biopha.2004.02.006_BIB3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00001721-199910000-00006","article-title":"Chronic fatigue syndrome and\/or fibromyalgia as a variation of antiphospholipid antibody syndrome: an explanatory model and approach to laboratory diagnosis","volume":"10","author":"Berg","year":"1999","journal-title":"Blood Coagul Fibrinolysis"},{"key":"10.1016\/j.biopha.2004.02.006_BIB4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1063-4584(98)80009-5","article-title":"Efficacy and tolerability of oral chondroitin sulfate as a symptomatic slow-acting drug for osteoarthritis (SYSADOA) in the treatment of knee osteoarthritis","volume":"6","author":"Bucsi","year":"1998","journal-title":"Osteoarthritis Cartilage"},{"key":"10.1016\/j.biopha.2004.02.006_BIB5","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.2460\/ajvr.1999.60.12.1552","article-title":"Scintigraphic evaluation of dogs with acute synovitis after treatment with glucosamine hydrochloride and chondroitin sulfate","volume":"60","author":"Canapp","year":"1999","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB6","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0031-6997(25)06945-5","article-title":"Actions of heparin in the atherosclerotic process","volume":"48","author":"Engelberg","year":"1996","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.biopha.2004.02.006_BIB7","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/(SICI)1097-0142(19990115)85:2<257::AID-CNCR1>3.0.CO;2-2","article-title":"Actions of heparin that may affect the malignant process","volume":"85","author":"Engelberg","year":"1999","journal-title":"Cancer"},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2004.02.006_BIB8","first-page":"1","article-title":"Current perspectives on low molecular weight heparins","volume":"19","author":"Fareed","year":"1993","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.biopha.2004.02.006_BIB9","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/j.1552-4604.1988.tb03184.x","article-title":"The antithrombotic activity and pharmacokinetics of enoxaparine, a low molecular weight heparin, in humans given a single subcutaneous dose of 20\u00a0to 80\u00a0mg","volume":"28","author":"Frydman","year":"1988","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.biopha.2004.02.006_BIB10","doi-asserted-by":"crossref","first-page":"S567","DOI":"10.1111\/j.1432-2277.1994.tb01445.x","article-title":"Low-dose heparin: a novel approach in immunosuppression","volume":"7","author":"Gorski","year":"1994","journal-title":"Transpl Int"},{"key":"10.1016\/j.biopha.2004.02.006_BIB11","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-0037-1612913","article-title":"Antithrombotic efficacy in a rat model of the low molecular weight heparin, reviparin sodium, administered by the oral route","volume":"85","author":"Hiebert","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.biopha.2004.02.006_BIB12","first-page":"111","article-title":"Oral heparins","volume":"48","author":"Hiebert","year":"2002","journal-title":"Clin Lab"},{"key":"10.1016\/j.biopha.2004.02.006_BIB13","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/0049-3848(76)90262-0","article-title":"The observation of heparin on endothelium after injection","volume":"8","author":"Hiebert","year":"1976","journal-title":"Thromb Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB14","first-page":"196","article-title":"Antithrombotic activity of orally administered low molecular weight heparin (logiparin) in a rat model","volume":"30","author":"Hiebert","year":"2000","journal-title":"Haemostasis"},{"key":"10.1016\/j.biopha.2004.02.006_BIB15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00005344-199607000-00005","article-title":"Antithrombotic activity of oral unfractionated heparin","volume":"28","author":"Hiebert","year":"1996","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.biopha.2004.02.006_BIB16","first-page":"341","article-title":"The heparin target organ\u2014the endothelium. Studies in a rat model","volume":"86","author":"Hiebert","year":"1993","journal-title":"Quart J Med"},{"key":"10.1016\/j.biopha.2004.02.006_BIB17","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1023\/A:1016161001013","article-title":"Tissue distribution of [14C] sucrose octasulfate following oral administration to rats","volume":"19","author":"Hiebert","year":"2002","journal-title":"Pharm Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB18","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1139\/y99-140","article-title":"Tissue distribution and antithrombotic activity of unlabeled or 14C-labeled porcine intestinal mucosal heparin following administration to rats by the oral route","volume":"78","author":"Hiebert","year":"2000","journal-title":"Can J Physiol Pharmacol"},{"key":"10.1016\/j.biopha.2004.02.006_BIB19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1021\/js9502736","article-title":"Accelerated stability studies of heparin","volume":"85","author":"Jandik","year":"1996","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.biopha.2004.02.006_BIB20","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/9780470110447.ch4","article-title":"Determination of heparin and related sulfated mucopolysaccharides","volume":"24","author":"Jaques","year":"1977","journal-title":"Methods Biochem Anal"},{"key":"10.1016\/j.biopha.2004.02.006_BIB21","first-page":"122","article-title":"Evidence from endothelium of gastric absorption of heparin and of dextran sulfates 8000","volume":"117","author":"Jaques","year":"1991","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.biopha.2004.02.006_BIB22","first-page":"422","article-title":"Determination of absolute amounts of heparin and of dextran sulfate in plasma in microgram quantities","volume":"115","author":"Jaques","year":"1990","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.biopha.2004.02.006_BIB23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1001\/archinte.1994.00420010073009","article-title":"A randomized trial comparing activated thromboplastin time with heparin assay in patients with acute venous thromboembolism requiring large daily doses of heparin","volume":"154","author":"Levine","year":"1994","journal-title":"Arch Int Med"},{"key":"10.1016\/j.biopha.2004.02.006_BIB24","first-page":"135","article-title":"Heparin, heparinoids and heparin oligosaccharides: structure and biological activities","author":"Linhardt","year":"1990"},{"key":"10.1016\/j.biopha.2004.02.006_BIB25","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1177\/030006059202000106","article-title":"Lowering of plasma viscosity by the oral administration of the glycosaminoglycan sulodexide in patients with peripheral vascular disease","volume":"20","author":"Lunetta","year":"1992","journal-title":"J Int Med Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB26","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1038\/ki.1995.147","article-title":"Heparin lowers blood pressure: biological and clinical perspectives","volume":"47","author":"Mandal","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.biopha.2004.02.006_BIB27","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1177\/096721090100900302","article-title":"Development of oral heparin therapy for prophylaxis and treatment of deep venous thrombosis","volume":"9","author":"Money","year":"2001","journal-title":"Cardiovasc Surg"},{"key":"10.1016\/j.biopha.2004.02.006_BIB28","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/S0090-4295(00)00685-3","article-title":"Pentosan polysulfate therapy for chronic nonbacterial prostatitis (chronic pelvic pain syndrome category IIIA): a prospective multicenter clinical trial","volume":"56","author":"Nickel","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.biopha.2004.02.006_BIB29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/0049-3848(90)90062-H","article-title":"Pharmacokinetic properties of size-homogenous heparin oligosaccharides","volume":"59","author":"Palm","year":"1990","journal-title":"Thromb Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0049-3848(99)00125-5","article-title":"The binding of unfractionated heparin and low molecular weight heparin to thrombin-activated human endothelial cells","volume":"96","author":"Young","year":"1999","journal-title":"Thromb Res"},{"key":"10.1016\/j.biopha.2004.02.006_BIB31","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1055\/s-0037-1615131","article-title":"Heparin and cancer","volume":"80","author":"Zacharski","year":"1998","journal-title":"Thromb Haemost"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332204000861?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332204000861?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T10:31:56Z","timestamp":1760092316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332204000861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,7]]},"references-count":31,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2004,7]]}},"alternative-id":["S0753332204000861"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2004.02.006","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2004,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tissue distribution of the low molecular weight heparin, tinzaparin, following administration to rats by the oral route","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2004.02.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"converted-article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2004 \u00c9ditions scientifiques et m\u00e9dicales Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}